9 Citations (Scopus)

Abstract

Poor glycemic control is related to an increased risk of endstage renal disease (ESRD). This study investigated the association between medication adherence and the risk of ESRD in patients with newly diagnosed diabetes mellitus. In this population-based cohort study, we used the TaiwanNational Health Insurance Research Database (NHIRD) to identify 559,864 patients with newly diagnosed or treated diabetes mellitus who were ages from 20 to 85 years between 2001 and 2008. We identified 1695 patients with ESRD during the study period. The mean follow-up time of the patients with ESRD was 5.7 years. Time-dependent Cox proportional hazards regression was performed to estimate the hazard ratios for ESRD among the patients with newly diagnosed diabetes mellitus. After adjustment for various covariates, nonadherence to oral antihyperglycemic medication (OAM) was associated with a higher risk of ESRD compared with adherence to OAM (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.01-1.23). The effects of nonadherence to OAM on the risk of ESRD were significant for patients without hypertension, without gout, without chronic kidney disease, undergoing OAM polytherapy, and undergoing metformin polytherapy (HR [95% CIs], 1.18 [1.00-1.39], 1.13 [1.02- 1.26], 1.17 [1.03-1.33], 1.22 [1.08-1.38], and 1.13 [1.02-1.25], respectively). In conclusion, nonadherence to OAM therapy is associated with ESRD. Adherence to medication therapy can prevent the progressive loss of renal function and ESRD for patients with diabetes.

Original languageEnglish
Pages (from-to)e2051
JournalMedicine (United States)
Volume94
Issue number47
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Hypoglycemic Agents
Chronic Kidney Failure
Kidney
Diabetes Mellitus
Medication Adherence
Gout
Metformin
Health Insurance
Chronic Renal Insufficiency
Cohort Studies
Databases
Confidence Intervals
Hypertension
Therapeutics
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nonadherence of oral antihyperglycemic medication will increase risk of end-stage renal disease. / Chang, Po Ya; Chien, Li Nien; Lin, Yuh Feng; Chiou, Hung Yi; Chiu, Wen Ta.

In: Medicine (United States), Vol. 94, No. 47, 01.11.2015, p. e2051.

Research output: Contribution to journalArticle

@article{120162beb58a4c19934f2dfae4c2b51f,
title = "Nonadherence of oral antihyperglycemic medication will increase risk of end-stage renal disease",
abstract = "Poor glycemic control is related to an increased risk of endstage renal disease (ESRD). This study investigated the association between medication adherence and the risk of ESRD in patients with newly diagnosed diabetes mellitus. In this population-based cohort study, we used the TaiwanNational Health Insurance Research Database (NHIRD) to identify 559,864 patients with newly diagnosed or treated diabetes mellitus who were ages from 20 to 85 years between 2001 and 2008. We identified 1695 patients with ESRD during the study period. The mean follow-up time of the patients with ESRD was 5.7 years. Time-dependent Cox proportional hazards regression was performed to estimate the hazard ratios for ESRD among the patients with newly diagnosed diabetes mellitus. After adjustment for various covariates, nonadherence to oral antihyperglycemic medication (OAM) was associated with a higher risk of ESRD compared with adherence to OAM (hazard ratio [HR], 1.11; 95{\%} confidence interval [CI], 1.01-1.23). The effects of nonadherence to OAM on the risk of ESRD were significant for patients without hypertension, without gout, without chronic kidney disease, undergoing OAM polytherapy, and undergoing metformin polytherapy (HR [95{\%} CIs], 1.18 [1.00-1.39], 1.13 [1.02- 1.26], 1.17 [1.03-1.33], 1.22 [1.08-1.38], and 1.13 [1.02-1.25], respectively). In conclusion, nonadherence to OAM therapy is associated with ESRD. Adherence to medication therapy can prevent the progressive loss of renal function and ESRD for patients with diabetes.",
author = "Chang, {Po Ya} and Chien, {Li Nien} and Lin, {Yuh Feng} and Chiou, {Hung Yi} and Chiu, {Wen Ta}",
year = "2015",
month = "11",
day = "1",
doi = "10.1097/MD.0000000000002051",
language = "English",
volume = "94",
pages = "e2051",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "47",

}

TY - JOUR

T1 - Nonadherence of oral antihyperglycemic medication will increase risk of end-stage renal disease

AU - Chang, Po Ya

AU - Chien, Li Nien

AU - Lin, Yuh Feng

AU - Chiou, Hung Yi

AU - Chiu, Wen Ta

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Poor glycemic control is related to an increased risk of endstage renal disease (ESRD). This study investigated the association between medication adherence and the risk of ESRD in patients with newly diagnosed diabetes mellitus. In this population-based cohort study, we used the TaiwanNational Health Insurance Research Database (NHIRD) to identify 559,864 patients with newly diagnosed or treated diabetes mellitus who were ages from 20 to 85 years between 2001 and 2008. We identified 1695 patients with ESRD during the study period. The mean follow-up time of the patients with ESRD was 5.7 years. Time-dependent Cox proportional hazards regression was performed to estimate the hazard ratios for ESRD among the patients with newly diagnosed diabetes mellitus. After adjustment for various covariates, nonadherence to oral antihyperglycemic medication (OAM) was associated with a higher risk of ESRD compared with adherence to OAM (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.01-1.23). The effects of nonadherence to OAM on the risk of ESRD were significant for patients without hypertension, without gout, without chronic kidney disease, undergoing OAM polytherapy, and undergoing metformin polytherapy (HR [95% CIs], 1.18 [1.00-1.39], 1.13 [1.02- 1.26], 1.17 [1.03-1.33], 1.22 [1.08-1.38], and 1.13 [1.02-1.25], respectively). In conclusion, nonadherence to OAM therapy is associated with ESRD. Adherence to medication therapy can prevent the progressive loss of renal function and ESRD for patients with diabetes.

AB - Poor glycemic control is related to an increased risk of endstage renal disease (ESRD). This study investigated the association between medication adherence and the risk of ESRD in patients with newly diagnosed diabetes mellitus. In this population-based cohort study, we used the TaiwanNational Health Insurance Research Database (NHIRD) to identify 559,864 patients with newly diagnosed or treated diabetes mellitus who were ages from 20 to 85 years between 2001 and 2008. We identified 1695 patients with ESRD during the study period. The mean follow-up time of the patients with ESRD was 5.7 years. Time-dependent Cox proportional hazards regression was performed to estimate the hazard ratios for ESRD among the patients with newly diagnosed diabetes mellitus. After adjustment for various covariates, nonadherence to oral antihyperglycemic medication (OAM) was associated with a higher risk of ESRD compared with adherence to OAM (hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.01-1.23). The effects of nonadherence to OAM on the risk of ESRD were significant for patients without hypertension, without gout, without chronic kidney disease, undergoing OAM polytherapy, and undergoing metformin polytherapy (HR [95% CIs], 1.18 [1.00-1.39], 1.13 [1.02- 1.26], 1.17 [1.03-1.33], 1.22 [1.08-1.38], and 1.13 [1.02-1.25], respectively). In conclusion, nonadherence to OAM therapy is associated with ESRD. Adherence to medication therapy can prevent the progressive loss of renal function and ESRD for patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84979852527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979852527&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000002051

DO - 10.1097/MD.0000000000002051

M3 - Article

VL - 94

SP - e2051

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 47

ER -